Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection

Table 2 Associations of serum FGF-21 levels

(a)
Variable	(n)	Log₁₀Serum FGF-21, mean (SD)	p value
Gender	Male (26)	2.39 (0.40)
	Female (6)	2.46 (0.48)	0.71
Ethnicity	Caucasian (27)	2.44 (0.33)
	Black African (5)	2.21 (0.72)	0.27
Current ART	PI (7)	2.29 (0.26)
	No PI (25)	2.43 (0.44)	0.43
Lifetime ART	d-drugs (8)	2.38 (0.26)
	No d-drugs (24)	2.41 (0.45)	0.86
	AZT (23)	2.44 (0.42)
	No AZT (9)	2.30 (0.39)	0.41
Lipodystrophy	Yes (10)	2.50 (0.27)
	No (22)	2.36 (0.46)	0.39
Lipid-lowering therapy	Yes (8)	2.32 (0.52)
	No (24)	2.43 (0.38)	0.53
(b)
Variable		Correlation coefficient (r)	p value
Age		−0.07	0.69
Duration of diagnosed HIV infection		−0.08	0.67
Duration of lifetime ART	Total	0.12	0.50
	d-drug	0.01	0.97
	AZT	0.13	0.47
CD4 lymphocyte count	Nadir	−0.29	0.14
	Current	0.36	0.042
CD4 count gain	(Current minus nadir)	0.45	0.016
Serum ALT		0.27	0.14
Plasma glucose		0.34	0.06
Serum lipids	Total cholesterol	−0.03	0.87
	HDL cholesterol	0.02	0.90
	Non-HDL cholesterol	−0.06	0.75
Mitochondrial histochemistry	COX defect (log₁₀)	−0.02	0.91

(a) binary variables; (b) continuous variables. (PI, protease inhibitor; AZT, zidovudine; d-drug, dideoxynucleoside analogue; ART, anti-retroviral therapy; ALT, alanine transaminase; HDL, high density lipoprotein).
Bold type indicates statistically significant associations.

ISSN: 1742-6405